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To address the global burden of sickle cell disease (SCD) and the need for novel therapies, the
American Society of Hematology partnered with the US Food and Drug Administration to
engage the work of 7 panels of clinicians, investigators, and patients to develop consensus
recommendations for clinical trial end points. The panels conducted their work through
literature reviews, assessment of available evidence, and expert judgment focusing on end
points related to: patient-reported outcomes (PROs), pain (non-PROs), the brain, end-organ
considerations, biomarkers, measurement of cure, and low-resource settings. This article
presents the ﬁndings and recommendations of the PROs, pain, and brain panels, as well as
relevant ﬁndings and recommendations from the biomarkers panel. The panels identify
end points, where there were supporting data, to use in clinical trials of SCD. In addition,
the panels discuss where further research is needed to support the development and
validation of additional clinical trial end points.
Introduction
Sickle cell disease (SCD) is the most common inherited red blood cell disorder in the United States,
affecting 70 000 to 100 000 Americans.1 Although the molecular basis of SCD was established
decades ago, it has been challenging to translate this knowledge into the development of effective
therapies. To improve therapeutic options, clinical trials using carefully defined and appropriately
chosen end points are needed that can capture patient benefit. These end points will enable
scientific advancement, improvements in patient care, and product approvals.
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As part of a multifaceted initiative addressing the global burden of
SCD, the American Society of Hematology (ASH) partnered with
the US Food and Drug Administration (FDA) to engage the work
of 7 panels of clinicians, investigators, and patients to develop
consensus recommendations for SCD end points. The panels
conducted their work through literature reviews, assessment of
available evidence, and expert judgment focusing on end points
related to: patient-reported outcomes (PROs), pain; nonpatient-
reported measures of pain; the brain; other end-organ considerations;
biomarkers; measurement of cure; and those appropriate for low-
resource settings. In conducting their reviews, the panels consid-
ered a broad range of end-point definitions including biomarkers as
well as fully qualified clinical end points denoting clinical benefit that
could be used for regulatory approval. Clinical benefit was defined
as what a patient would want from a therapeutic procedure, such
as improved survival, symptom improvement, or decreased risk of
developing disease or morbidity (eg, stroke). Ideal end points should
reflect patient desires, and integrate objective measurements
to assess disease severity and progression. Ideally, an end point
should be easy to measure accurately at low cost and at low burden
for the patient and the research team. Furthermore, it should be
interpretable, clinically relevant, and available to be measured in all
patients in a study facilitating complete data collection.
The results of the panels’ work were presented and discussed at
a public workshop in October 2018 attended by 188 in-person and
750 online attendees via livestream from 20 countries. Intra- and
interpanel discussions as well as exchanges with attendees further
informed the process. This article presents the findings and recom-
mendations of the PROs, pain, and brain panels, as well as relevant
findings and recommendations from the biomarkers panel. Findings and
recommendations from the other panels are reported separately.2
The workshop recognized significant differences between definition
of end points and biomarkers applied as end points. Building off of
the Biomarkers, End pointS, and other Tools (BEST) resource,3 the
panels concurred with the definition of a biomarker as a defined
characteristic(s) measured as an indicator of normal biological or
pathogenic processes, or responses to an exposure or intervention.
A biomarker is not an “end point” that evaluates how an individual
feels, functions, or survives. A full biomarker description includes the
biomarker name, the source/matrix, the measurable character-
istic(s), and the analytic method used to measure the biomarker.
Biomarkers can be further classified as those that, for example,
stratify susceptibility/risk biomarker, diagnosis, disease/product
monitoring, and prognosis. Although many biomarkers associated
with SCD complications represent findings from single and small
study populations, the authors attempted to discriminate those
biomarkers that are well established from those that are used for
research purposes. Specifically, to evaluate a biomarker in SCD,
several pieces of information were evaluated and varied for each
biomarker, including but not limited to evidence (quantity and quality
of) on measurability, sensitivity, specificity, and reliability, as well as
laboratory-to-laboratory reproducibility. These characteristics are
defined as analytical validation for a given biomarker by the BEST
document and helped guide committee views on defining the
presence and value of biomarkers in SCD.
End points for PROs in SCD
The FDA and the National Institutes of Health define a PRO as
“any report of the status of a patient’s health condition that comes
directly from the patient, without interpretation of the patient’s
response by a clinician or anyone else.”4(p2) Instruments to measure
PROs in a quantitative manner and capture the patient’s voice
complement traditional measures of efficacy such as survival and
frequency as well as duration of hospitalization.5
The most common SCD symptoms include outcomes that are
subjective, such as pain and fatigue. Therefore, it is imperative
to use PROs as a clinical end point to measure efficacy in therapeutic
trials. The PROs panel determined that 3 key PRO domains are
particularly salient in SCD: pain (acute and chronic), affect (emotional
impact, sleep quality, and fatigue), and functioning (social, physical,
and cognitive function, as well as self-efficacy for disease manage-
ment and occupational function). Although other PRO end points are
important and valuable for patients with SCD, in choosing these 3
domains the PROs panel considered whether the outcomes would
be relevant within a regulatory framework for assessing therapeutic
products or devices. The panel then determined whether there were
existing tools to measure the most relevant facets of those domains
and evaluated the evidence supporting their use in SCD.
Extensive work over the past 2 decades has resulted in reliable
and valid methods of measuring PROs that incorporate prior
research, are valid across multiple conditions, use the most
advanced current knowledge of psychometrics and testing, and
minimize patient/participant burden in data collection. To capitalize
on this work and further the goal of developing a common core set
of PROs, the PROs panel focused on 2 core families of PROs, each
with significant prior work in SCD. Overall, the panel considered the
ages of the trial population to be an important criterion in selecting
appropriate measures.
The first of these groups, the Patient-Reported Outcomes Measure-
ment Information System (PROMIS), encapsulates a multidisciplinary
effort to develop measures calibrated to patient health domains
of greatest health impact.6 PROMIS measures are available in
broad age ranges and are closely related to the Adult Sickle Cell
Quality of Life Measurement Information System (ASCQ-ME)
adult SCD-specific measures that were developed alongside
them. The second is the Pediatric Quality of Life Inventory (PedsQL),
which contains both general and SCD-specific modules of PROs
for children.
An important consideration in measure selection is developmental
level. The panel recognized the advantage of using PROMIS when
both children and adults are the target population as it is a well-
accepted multidimensional PRO set that allows for assessment
and comparison across the lifespan. ASCQ-ME, although developed
specifically for SCD, is validated only for adults, whereas PedsQL is
validated for children only. In addition, very young childrenmay require
the use of proxy reports because many PRO measures require
abstract or complex cognitive processes that are not appropriate for
younger children. Parent or proxy measures can complement the
use of child self-reports in settings in which the child is too young or
not able cognitively to self-report. However, parent and child reports
are not interchangeable and would need to be analyzed separately.
Thus, child self-report is the best option for capturing PROs when
possible.
In keeping with the accepted psychometric standards expected
for PROs, the PROs panel evaluated measures of their validity,
reliability, and responsiveness to change in clinical status, both
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natural history of the illness and treatment response, when such
evidence was available.7,8 Participant burden and an understanding
of the clinical interpretation of the score and of a change in score
were also considered. The acceptability of these PRO end points as
coprimary, secondary, or “composite” end points for regulatory
purposes will likely depend on the mechanism of action and
anticipated therapeutic effect(s) of a product/device. PROs and
means for measuring them were considered for the domains of
acute and chronic pain, affect, and functioning. A separate article by
this group discusses use of PROs in low-resource settings.2
Measuring patient-reported pain outcomes
Pain is the most common symptom of SCD9,10 but its etiology is
complex and multifactorial.11 An interplay of disease, genetic,
psychological, and environmental factors contributes to develop-
ment of a pain phenotype. Pain in SCD has been categorized as
acute, chronic, or acute in the presence of chronic pain; and recent
expert consensus suggests subdividing chronic pain in SCD into
that associated with another identifiable cause and that which is
not. Multiple pain mechanisms may be active at a given time.
Furthermore, the pain phenotype among individuals with SCD
can exhibit remarkable diversity, for reasons that have not been
completely elucidated.
For example, painful crises vary in duration and intensity from person
to person and over time for an individual person, but have
a definable beginning and end. The most appropriate composite
measure of the response of crisis to treatment may depend on the
time period being observed (eg, at baseline, beginning to end of
crisis, duration of an acute care visit, duration of a hospitalization),
the initial level of pain, and appropriate measures of the significance
of the reduction, such as patients’ or clinicians’ judgement of
improvement or readiness for discharge. Whether an intervention
improves the responsivity of pain to standard therapy, such as
opioid analgesics (an “opioid sparing effect”), requires simulta-
neous measurement of patient-reported pain intensity and anal-
gesic use. The measurement of a therapeutic response of an
intervention targeted at chronic pain will require different methods.
Thus, unidimensional measures of pain intensity must be integrated
with other relevant measures, such as multidimensional PRO
measures of pain, time, and analgesic use, and used in a manner
suitable for the setting and expected natural history of the pain
phenomenon being studied.
Reduction in the frequency of acute painful episodes (vaso-
occlusive crises [VOCs]) is accepted by the FDA as an important
clinical outcome and an established surrogate end point of clinical
benefit for SCD. Approval of the currently available agents
(hydroxyurea and L-glutamine) were based on demonstrated
improvement in the rate of painful crises among patients with
SCD in randomized placebo-controlled trials. As a clinical trial end
point (primary or key secondary end point), measures of pain
intensity and interference should be patient-reported. Such PROs
can be integrated into a composite end point that includes non-
PRO pain measures (discussed in "Pain intensity"). Future studies
should better define how non-PRO pain measures correlate with
PROs. Nonetheless, non-PRO end points, many of which are in the
early stages of validation, may be useful as correlative/secondary
end points and drive development of mechanism-targeted therapies
for pain in SCD.
Changes in acute pain are a vital end point for many interventions
for SCD. In addition to changes in pain intensity, clinically important
improvements in acute pain have been operationalized in a number
of ways, including cessation of parenteral opioids for at least
5 hours, reported pain relief, ability to walk if previously ambulatory,
or a decision that pain was low enough for discharge from acute
care.12,13 In studies of preventive interventions, reduction in the
rates of acute crises and utilization of opioid analgesics have also
been used.14-16 In many cases, acute care utilization has been used
as a proxy for crisis frequency, which likely is an underestimate of
overall crisis pain.13
In the future, pain-related outcome measures should capture what
patients want from a therapy, such as reductions in pain frequency,
pain intensity, suffering, and interference with daily activities and life
goals. Additional challenges lie in the inability to predict or classify
patients at high risk for chronic pain through the use of biomarkers.
The PROs panel considered measurements for pain intensity,
interference, and behavior, applicable to both acute and chronic
pain associated with SCD.
Pain intensity. In children, ordinal categorical scales, visual
analog scales (VASs), and numeric rating scales (NRSs) are
generally accepted as valid and reliable for measuring pain
intensity, although this must be tempered by developmental
considerations.17-19 Measurement of pain intensity in children
below the ages of 7 to 8 years is particularly complicated.
NRSs,20-24 VASs,22-24 and the Faces Pain Scale–Revised (FPS-
R)22,25,26 have all been used in SCD in patients at least as young as
8 years of age, mainly for measuring acute pain, and have high
convergent validity in general. To the extent that a study sample
includes very young children and no adults, the FPS-R may be
appropriate, although it may be unreliable in children younger than
7 years.23,27 For older children and particularly mixed populations
with adults, an NRS or VAS is likely most appropriate.
For adults and children 8 years and older,27 pain intensity should be
measured using a VAS or an 11-point, 0 to 10 NRS with anchoring
prompts at the low end (“none”) and the high end (“as bad as you
can imagine”). An NRS scale is implemented in PROMIS 1a and as
part of other multidimensional pain measures. It has been validated
in SCD and is sensitive to chronic pain, improvements in acute pain,
and therapeutic effects.12,13,23 VASs are less often used in clinical
practice and require adequate cognitive and visuospatial abilities;
they also require that the patient be able to see and manipulate the
scale. In participants at least 8 years old, the PROs panel
recommends use of an 11-point NRS or an appropriately
reproduced and administered VAS as a measure of pain intensity.
With respect to measuring change in pain as a clinical outcome,
patient-reported clinically important differences tend to be pro-
portional to initial pain intensity (such as 30% reduction) rather than
an absolute change and both should be reported.28 For pain
outcomes during hospitalizations or acute care visits, methods
should include consideration of confounding of pain intensity
with other factors affecting admission, discharge, and length of
stay. For acute/crisis pain managed at home, there is little
evidence regarding assessment to guide recommendations for
pain evaluation.14,21 Electronic diaries,29 or possibly ecological
momentary assessment,30,31 may be reasonable options. However,
the performance of these measures needs further investigation.
Reductions in chronic pain intensity or interference as an end point
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should account for the long duration of this symptom, such that
longer-term follow-up and sustained response should be preferred
in defining relevant end points. For chronic pain, established
instruments use time anchors to evaluate average, least, and
worst pain in a reasonable time period (such as 24 hours for the
Brief Pain Inventory [BPI]). However, no standard is established
for the use of time anchors. Anchors reflecting longer time
periods are likely to be more influenced by recall bias, and there
tend to be strong correlations among different time measures.32,33
Pain interference/impact and behavior. Pain interference
(often used synonymously with “impact”) is an important clinical end
point in addition to pain intensity.34 Although it is strongly correlated
with intensity, there is evidence that interference and intensity
are differentially responsive to intervention.35,36 The relationship
between self-reported pain interference scales and functional
outcomes may be indirect and attenuated,37,38 which argues for
more specific measures of function as an outcome.
In children 8 years and older, PedsQL, Pain Interference,39 and
PROMIS Pain Interference40 have established validity and reliability
and are responsive to changes in acute pain.41-43 Proxy reported
versions are available and also validated for use in SCD.44,45 In
adults, PROMIS Pain Interference was validated in adults with
SCD in a comparative study with ASCQ-ME and was found to
be sensitive to differences in the presence of clinical compli-
cations.46 ASCQ-ME Pain Impact was shown to be valid47 with
regard to overall SCD severity, but its longitudinal validity is not
yet established.
There is some evidence that the BPI Pain Interference scale is
superior to PROMIS measures on sensitivity to change, though
whether this is true in SCD is unknown48 and future research is
needed regarding its usefulness in SCD. The BPI’s inclusion of
validated pain intensity NRS and a similarly well-validated pain
interference scale allows for measurement of both pain intensity
and interference.
To assess pain interference and pain impact, the PROs panel
recommends the PROMIS Pain Interference measures for studies
of adult, pediatric, or mixed age groups; ASCQ-ME Pain Impact for
adults; and PedsQL, Pain Impact, and Pain and Hurt for children.
Alternatively, the BPI may be used for studies limited to adult
participants.
Pain behavior. PROMIS includes domains for Pain Behavior
and Pain Quality for use in children and adults. The PROMIS
pediatric Pain Behavior domain is a valid and reliable measure.48,49
Pain Behavior and Pain Quality domains have been used in adults
with SCD.46,47 For assessment of pain behavior, the PROs panel
recommends using the PROMIS Pain Behavior domain for children
and adults with SCD.
Measuring PROs related to affect
The PROs panel identified depression/negative emotional impact
and fatigue as the primary PROs in the affective domain.
Depression/negative emotional impact. For children, the
specific impact of SCD on emotional well-being is measured by
the Peds-QL, SCD Module Emotions measure, although the
SCD Module Worry measures (I and II) may be of secondary
interest. The Emotions module distinguished mild from severe
disease as operationalized in a validation study.41,50 In adults, the
ASCQ-ME Emotional Impact tool was developed specifically for
use in SCD, which shows some relationships to SCD disease
activity.46,47
The PROMIS Pediatric Depression and Anxiety tool may provide
reasonable measures of low mood and anxiety, which have some
advantages in comparison across conditions and in relation to other
measures of depressive symptoms. PROMIS Pediatric Depression,
Pediatric Anxiety, and Pediatric Anger scales have shown relation-
ships both to disease severity and changes in disease severity.40,42
The adult PROMIS Depression and Anxiety scales have not been
specifically evaluated in SCD. Although some work has been done
to compare it to older instruments, the Depression measure may be
less sensitive to the neurovegetative symptoms of Major Depres-
sive Disorder (MDD) than some other measures.51 Great caution
must be exercised in equating the “depression” measured by
these instruments with a diagnosis of MDD or generalizing from
changes in these scales in SCD to conclusions about the efficacy
of treatments for MDD in SCD.
To measure specific impact of SCD on emotional health, the PROs
panel recommends the PedsQL SCD Module Emotions measure
for children and the ASCQ-ME Emotional Impact measure for adults.
For more general measures of negative affect, and particularly when
mixed age samples are used, the panel recommends the PROMIS
Depression and Anxiety measures.
Fatigue. The PROMIS Pediatric Fatigue Scale has shown
preliminary evidence of validity and sensitivity to differences in
disease severity in children as well as in changes in the process
of crisis recovery.40,42 The PedsQL, Multidimensional Fatigue
Scale was validated in children with SCD.52 In adults, the PROMIS
Fatigue Short Form was examined in SCD and performed
adequately, with the advantage that it is a shorter and more
participant/patient-friendly measure than most against which
it was validated. PROMIS measures overall, including fatigue,
were sensitive to disease severity, though they explained less
unique variance in SCD severity than ASCQ-ME. However,
there is no SCD-specific fatigue measure included in ASCQ-ME47
because the PROMIS fatigue measures were validated in field studies.
To assess fatigue, the PROs panel recommends using PROMIS or
PedsQL, Fatigue measures in children and the PROMIS Fatigue
measure in adults.
Measuring PROs related to function
The PROs panel identified social, physical, and cognitive function-
ing, occupational functioning, and self-efficacy as primary functional
PROs associated with SCD.
Emotional/social, physical, cognitive domains. Both the
PROMIS measures and the PedsQL measures have been shown to
be valid and reliable. Currently, there are limited published data on
PROs over time in patients with SCD. There are data supporting
responsiveness of PedsQL, broadly in children with acute painful
crises,53,54 and its broad sensitivity to SCD disease severity,50,55-57
but no additional longitudinal data have been found using PROMIS
in adults or children.
Of note, the brain outcomes panel (see "End points for assessing
brain outcomes in SCD") identified The Canadian Occupational
Performance Measure (COPM) as a valid functional outcome
measure for the age range 6 to 65 years, designed for use by
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occupational therapists to assess client outcomes in the areas
of self-care, functional mobility, productivity, and leisure.58
Using a semistructured interview, the COPM is a 5-step process
that measures individual, client-identified problem areas in daily
function. Two scores for performance and satisfaction with
performance are obtained. The measure is sensitive to change
from an intervention. It requires clients to self-report problem
areas in daily life but is not entirely patient-reported. A clinically
significant change is 2 points from time 1 to time 2.59
Participants may change their perspective on priorities of daily
function over a prolonged period of time.
The PROs panel recommends using the relevant domains of the
PROMIS and ASCQ-ME in adults, and the PROMIS and PedsQL in
children, to measure emotional/social, physical, and cognitive
function PRO domains. The COPM may be used as an outcome
measure for functional capacity that integrates self-report and
expert interview.
Occupational status assessment. Assessment of functional
outcomes that includes occupational status is important and could
be directly influenced by therapeutics or devices. Two occupational
surveys were examined: (1) the World Health Organization (WHO)
Health and Work Performance Questionnaire (HPQ) designed to
assess indirect workplace cost secondary to health-related poor
work performance and work absence and (2) a single question
addressing current employment status that is part of the PhenX
toolkit and publicly available for use. The group recommends using
the 1-item PhenX question for assessment of employment status
and the more detailed HPQ to assess multiple factors related to
work performance.
Self-efficacy. Self-efficacy is the perceived ability to execute
courses of action and behaviors to achieve desired goals, such as
to care for oneself or manage an illness. Self-efficacy can potentially
be improved by medical interventions, such as medications that
increase patients’ cognitive abilities or reduce symptom burden.
Self-efficacy is 1 of the most potent predictors of behavior change
and disease self-management, positively related to adherence to
medication and treatment in general.60 The Sickle Cell Self-Efficacy
Scale (SCSES) is a measure of self-efficacy that has been validated
in adolescents and adults with SCD.61 There is preliminary
evidence that it is sensitive to interventions.62,63 Thus, the PRO
panel recommends using the SCSES to measure self-efficacy in
adolescents and adults with SCD.
Future directions in PROs in SCD
PROs allow the quantification of aspects of subjective experience,
facilitating incorporation of subjective improvements into rigorous
measures of treatment effect. It is likely that particular aspects of
disease pathophysiology relate more specifically to some such
experiences than others. One possible refinement of PROs is
developing rational combinations of PROs (symptoms) and more
objective measures (signs) that may then be linked to pathophys-
iology, thereby facilitating rational treatment development. Pain is an
area ripe for such developments. Among other reasons, certain pain
qualities have classically been linked to “neuropathic” as opposed
to “nociceptive” mechanisms and some instruments have been
developed that attempt to quantify the subjective correlates of these
mechanisms.64 Because of the causal complexity of the experi-
ence of pain and the relatively small effect sizes usually noted for
individual interventions, complexes of outcome measures that allow
evaluation of additive or synergistic effects of targeting multiple
mechanisms would be highly desirable.
Table 1 summarizes the PROs panel’s recommended approaches
to measuring PROs in patients with SCD.
End points for assessing pain in patients
with SCD (non-PROs)
The experience of pain is always subjective and thus the gold standard
of pain assessment is patient self-report, as described in the previous
sections. Individuals may also experience pain in the absence of
identifiable tissue damage or a known pathophysiological cause.
To accurately measure the pain experience of people with SCD and
thereby measure its response to therapeutic interventions, multidi-
mensional assessments are necessary.
Although the PROs panel focused on measures of pain intensity,
interference, and pain behaviors, the non-PRO pain panel focused
on measures of pain control and function, pain endophenotype,
underlying pain mechanisms, and promising measures in animal
models with potential for translation to humans.
Measures of pain control and function
A diverse set of measures of pain control and function were considered.
These included health care utilization (HCU), analgesic use, missed days
school/work, physical activity, and facial expression analysis.
HCU. HCU has been a standard surrogate end point for
evaluating pain in SCD and is easily obtained from the medical
record (unless care is sought at multiple sites). Total number of
emergency department visits and hospitalizations, and where
available, acute care clinic visits are the primary end points cited
in the literature. These may be considered as proxies for
pain.11,65-67 Additionally, hospital length of stay has been used to
measure HCU. Given the current state of care in SCD, HCU may
not be able to differentiate between acute and chronic pain and may
be influenced by a number of other factors, such as mental health,
socioeconomic status, and proximity to care. Ideally, acute HCU
could serve as an end point to measure acute pain. However, given
the difficulty in differentiating acute pain crises and exacerbations of
chronic pain in SCD, it is likely that there is considerable mixing of
the 2 phenomena, calling into question the accuracy of this end
point. HCU may more accurately represent acute pain in children as
they are less likely to have chronic pain, especially in the preteen
age group.
Analgesic use. Analgesic use, or more typically opioid sparing,
has been a common surrogate end point for pain trials whether SCD-
related or not.7,15,68 This end point can be used in pharmacologic and
nonpharmacologic trials. Given the prevalence of opioids for treating
both acute and chronic pain in SCD, analgesic use could likely be used
in acute and/or chronic pain. However, data on nonopioid medication
and its efficacy in SCD aremixed; thus, it may be premature to consider
use of other analgesics as an end point.
The number of opioid doses or total opioid dose can be used
to measure acute pain; however, this may be affected by patient use
of home opioids. Home opioid use could be tracked using an e-cap
or electronic delivery system. Opioid delivery through patient-
controlled analgesia may be the best metric for opioid use in the
acute setting for hospitalized patients. Opioid utilization measured
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in morphine equivalent units would be most appropriate for
measuring chronic pain.
Missed days at school or work. School attendance has
been used as a surrogate end point in studies of adolescents
with chronic pain and can be an objective measure of functional
outcomes.69,70 Collected objectively, it can also be used to
measure response to a multidisciplinary function-based therapy
for chronic pain.71 However, both school and work attendance
are influenced by multiple other psychosocial factors and there
is limited evaluation of these measures in the SCD population.72
School or work records would be needed to make this an
accurate non-PRO measure, requiring cooperation of schools
and/or employers. Furthermore, the high rate of unemployment
in adults with SCD may make work attendance less relevant for
some patients.73
Physical activity. Physical function measured by actigraphy has
been used as a surrogate end point in studies of chronic pain.74 A
composite measure of pain and activity may be better than other
measures to evaluate outcomes in individuals with bone/joint in-
volvement. However, there is no available literature in SCD and physical
activity measures do not inform much about pain mechanisms.
Facial expression analysis. Alterations in facial expressions in
response to pain occur in animals and humans.75,76 Mouse grimace
scale scores using facial images of sickle and control mice have
been used.77 In humans, several studies have demonstrated the
validity of using facial expressions for quantifying pain.76,78,79
Pain can be quantified objectively from remote access using the
subject’s images communicated through cell phones or other
media, which is most effective for pediatric settings and to assess
patients remotely. However, this area requires significant re-
search and development of algorithms to accurately quantify
pain without interference from other factors to eliminate false-
positives or false-negatives.
Measures of pain endophenotype
Pain endophenotype appears to be an important contributor to pain
experience. Preexisting vulnerabilities along with disease-related
factors contribute to differences in pain-related peripheral and
central nervous system (CNS) structure and function that leads to
individual differences in pain endophenotype.80 Quantitative sensory
testing (QST) and functional neuroimaging with or without
electrophysiological studies have been used in SCD and are the
most commonly used methodologies.
QST. QST encompasses several psychophysical testing modalities
to evaluate the sensitivity of the somatosensory system. Sensitivity
assessed includes both stimuli detection and pain produced by the
stimuli. Stimuli include thermal (heat, cold) and mechanical (pressure)
modalities.68,81 QST is a psychophysical tool that allows for the
assessment of alterations, differences, or variations in pain sensitivity
between patients and controls or within a patient over time or between
disease states (ie, baseline vs acute pain). These differences can suggest
altered pain processing at the level of the peripheral and/or CNS.
It has been used to assess patients during their baseline state of
health and in both acute and chronic pain states. It has been
validated in children as young as 7 years of age. QST has been
used as an indirect end point in children and adults with SCD82-86 and in
other conditions with pain.87-89 A variety of QST protocols exist
that attempt to differentiate alterations in peripheral vs central pain
pathways; however, it can be difficult to determine clear-cut differences.
Multiple examples in which QST has been used as an outcome/end
point in clinical trials have been published.90-99 To date, the majority
of QST data for patients with SCD are derived from descriptive
Table 1. Recommended end points and measures for PROs in SCD
Outcome/End point Recommended measurement/tool(s)
Pain
Intensity For patients at least 8 y of age, an 11-point NRS or appropriately reproduced and administered VAS
Interference/impact PROMIS Pain Interference measures for studies of adult, pediatric, or mixed age groups
ASCQ-ME Pain Impact for adults or the Brief Pain Impact for adults
PedsQL Pain Impact and Pain and Hurt for children
Behavior PROMIS Pain Behavior domain for children and adults
Affect
Depression/negative emotional impact PedsQL SCD Module Emotions measure for children
ASCQ-ME Emotional Impact measure for adults
PROMIS Depression and Anxiety measures for more general measures of negative affect, particularly when mixed age samples are
used
Fatigue PROMIS or PedsQL Fatigue measures in children
PROMIS Fatigue measure in adults
Function
Emotional/social, physical, cognitive domains Relevant domains of the PROMIS and ASCQ-ME in adults and PROMIS and PedsQL in children to measure emotional/social,
physical, and cognitive function PRO domains
The Canadian Occupational Performance Measure may be used to measure functional capacity that integrates self-report and expert
interview
Occupational status One item in PhenX for assessment of employment status and the more detailed WHO’s Health and Work Performance Questionnaire
to assess multiple factors related to work performance
Self-efficacy Sickle Cell Efficiency Scale to measure self-efficacy in adolescents and adults with SCD
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studies. There are no published data in which QST has been used
as an end point in a clinical trial targeted at pain treatment. Studies
have correlated QST outcomes with fetal hemoglobin levels,100
evaluated the reactivity of cytokines in patients with SCD after
the induction of experimental pain using QST,101 and evaluated
the vasoconstriction response to the application of heat pain.102
All studies have been conducted in patients during their baseline
“healthy” state or immediately following an acute painful event.82-86,103,104
Murine studies have also been conducted using similar QST
assessments and show similar findings to results in humans with
increased heat, cold, and mechanical sensitivity in SCD mice as
compared with control mice.105-107
Several challenges exist when operationalizing QST as an end point
in a clinical trial. These include: (1) costly equipment; (2) time-
intensive protocols; (3) variability in methods across sites; (4) the
fact that it is not an assessment of pain intensity or morbidity from
pain and cannot replace PROs of pain and function; (5) lack of
clarity of the clinically meaningful QST threshold or change in QST
threshold/outcomes102; (6) outcomes that are associated with
psychological comorbidities; and (7) lack of longitudinal data for
QST assessments in patients with SCD.
Imaging and electrophysiological studies. Brain imaging
and electrophysiological studies such as functional magnetic
resonance imaging (MRI; fMRI), scalp electroencephalography
(EEG), and positron emission tomography have been used to
delineate cerebral signatures of pain and analgesia. Other imaging-
based measures such as diffusion tensor imaging, spectroscopy,
and brain volumetric imaging are also being used to understand
changes in brain related to pain, especially chronic pain. Experience
in SCD pain with these methodologies has been limited and
relatively recent.
Imaging and electrophysiological studies have improved our
understanding of the pathways involved in pain perception and
modulation.108,109 Some features such as connectivity patterns
have been used to identify patients with certain pain endopheno-
types and some of these specific end points have been used as end
points for drugs in managing pain in non-SCD conditions.96,110-112
Pilot studies and comparative studies have been completed in
SCD comparing SCD patients with healthy controls.113 Associa-
tions between clinical pain burden and evoked pain have been
shown in pilot studies.114,115 Although these approaches can
objectively assess pain processing at the central level, nociceptive
stimuli trigger a variety of responses that are part of the multidimensional
experience of pain; thus many, if not all, features of brain activity that
have been associated with pain are nonspecific. On the basis of current
brain-imaging techniques, pain cannot be quantified although
efforts are under way to further decode this information.116,117
EEG and magnetoencephalography are direct and noninvasive
measures of brain function and can provide novel insight into
nociceptive pathways. EEG has been used to assess the evoked
potential in response to a brief stimulus, which yields typical
responses that mainly originate from somatosensory, insular,
and cingulate cortices. Changes in the nociceptive pathways
affect the amplitudes of these responses and thus could serve
as a clinically useful measure of the integrity of nociceptive pathways
to the brain.118-120 The most commonly used EEG approach to pain
has been the assessment of evoked potentials in responses to brief
noxious stimuli of milliseconds in duration. This approach yields
a typical sequence of response and changes in the amplitude of
these responses suggest damage to nociceptive pathways.121
Studies have assessed anticipation-evoked potential in patients
with fibromyalgia and osteoarthritis.122
Furthermore, in some diseases with chronic pain (eg, fibromyalgia,
chronic back pain), a disinhibition or lack of habituation of evoked
responses to a noxious stimulus can be seen.123,124 A study
simultaneously recording fMRI and EEG showed that SCD
patients had increased activity in pain-processing regions.125,126
The major strength of these methodologies is high temporal
resolution in the range of milliseconds. Thus, these methodol-
ogies complement imaging methods, such as fMRI, which has
temporal resolution on the order of 1 to 2 seconds. However,
a major challenge for EEG in pain research is limited understanding
of the processes by which sensory and contextual information
translate into pain experience.
Measures of underlying pain mechanisms: pain/
vaso-occlusive crisis biomarkers
Given the subjective nature of pain and the difficulty distinguishing
between acute and chronic pain, laboratory-based, objective, and
quantitative biomarkers for acute VOCs are urgently needed. These
would be especially useful for clinical trials and genomic studies.
To identify possible biomarkers for VOCs, the biomarkers panel
conducted a PubMed query for “biomarker,” “pain,” and “sickle cell”
including any articles in which potential biomarkers were assessed
in human subjects with SCD during an acute pain crisis. Potential
biomarkers assessed in patients with SCD at steady state with high
and low rates of pain events were excluded. No biomarkers had
been validated. Although some laboratory values and genetic
modifiers are associated with higher or lower incidence of pain
events in patients with SCD, such as fetal hemoglobin levels and
coinheritance of a thalassemia,127 these do not change during
a pain event.
Some biomarkers linked to known aspects of SCD pathophys-
iology may be increased during a pain event: elevated C-reactive
protein128 or substance P (SP)129 as markers of inflammation;
microparticles130 or cell-free DNA131 as markers of increased tissue
infarction; or plasma-free heme,132 plasma arginine,133,134 and exhaled
nitric oxide135 as markers of hemolysis. nitric oxide, endothelial
progenitor cells,136 soluble VCAM,137 and vascular endothelial
growth factor138,139 may also capture vascular damage and
adhesion aspects of a pain crisis. None of these have been shown
to be clinically useful or are suitable as important end points in
studies of pain.
Other biomarkers address red cell or blood rheological
abnormalities,140-144 such as deformability or whole-blood
viscosity. Emerging technology also allows the measurement
of red cell deformability under a range of oxygen concentrations,
although as yet there is nothing to suggest that changes in this
deformability are in some way related to pain. Dense cells are
another related value, but the relationship between the percentage
of dense red blood cells and pain is inconsistent, showing different
results at different points in the pain cycle,140,145-149 possibly due
to destruction of dense cells during a pain event. Measuring only
1 aspect of rheology can be misleading, for example, the senicapoc
trial,150 dense cells were reduced but pain events increased, likely
due to increases in whole-blood viscosity. A more global picture
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using a microfluidic system may provide multiple measures of
blood rheology simultaneously: adhesion, deformability, and
viscosity,151,152 although there is no evidence as yet that micro-
fluidic measurements are useful biomarkers.
Another challenge is the clinical variability of SCD patients.153
Some patients have increased baseline hemolysis,154,155 inflam-
mation, or abnormal rheology. These values also vary by genotype,
with hemoglobin SC disease (HbSC) patients exhibiting higher
whole-blood viscosity than most homozygous SCD (HbSS) patients,
and differing in some fundamental aspects of pathophysiology.155
Although challenging, longitudinal monitoring of values for each
patient to determine their steady-state values may allow for
identification of significant worsening, predictive or diagnostic
of an acute pain event.
In summary, although there is significant literature and potential for
biomarker discovery in an acute VOC, further research is needed to
validate a biomarker for this complication and bring it to the bedside.
Measures of underlying pain mechanisms: circulating
biomarkers. Circulating biomarkers and their potential asso-
ciation with pain should be assessed with regard to their measurability,
sensitivity, specificity, and reproducibility. The biomarkers panel
considered the value of mast cell–associated biomarkers and
leukocyte-associated biomarkers.
Mast cell activation has been associated with both acute and
chronic pain in sickle mice.156 Tryptase (a marker of mast cell
activation) is elevated in the blood of sickle mice and SCD
patients with pain.156,157 Mast cells reside in tissues, cohabiting
with nerves and vasculature, promoting direct neurovascular
and neuroinflammatory interactions.158-160 Inhibition of mast
cells with imatinib significantly reduced circulating SP and
calcitonin gene-related peptide (CGRP) and release of several
cytokines from the skin of BERK sickle mice. c-kit/mast cell
inhibitor imatinib also prevented VOCs in patients with SCD in 2
separate case reports.161,162 Mast cell activation markers, tryptase
and chymase, and substances released frommast cells, SP, CGRP,
histamine, interleukin 6, monocyte chemoattractant protein 1,
tumor necrosis factor a, granulocyte-macrophage colony-stimulating
factor, and RANTES may have potential as biomarkers for SCD pain.
Activation of neutrophils in sickle mice and patients with SCD
has been reported.163
,164 Release of neutrophil extracellular
traps containing elastase, histones, and nucleosomes/DNA has
been observed in BERK sickle mice and patients with SCD.162-166
Elastase, a proteolytic enzyme released from activated leukocytes
mediates inflammation in the peripheral tissues and the dorsal root
ganglion, was demonstrated to contribute to neuropathic pain in
rodent models.167,168 Significantly increased circulating free DNA
by quantitative polymerase chain reaction has been demonstrated
in SCD patients in VOC compared with steady state.131 Therefore,
circulating elastase, nucleosomal DNA, and A1AT may be biomarkers
of chronic and acute pain in SCD.
Physiological measures of pain-sensing neurons in pain
pathways. Primary sensory neurons convey stimuli about touch
and pain to the CNS. Electrophysiological-recording studies
have shown that both nociceptive (C fiber and Ad fiber) and low
threshold tactile (Ab fiber) cutaneous primary afferent neurons in
sickle mice exhibit significantly increased ongoing “spontaneous”
activity, and increased responses to mechanical stimuli and cold
stimuli applied to the skin.106,107,169 Cellular patch-clamp and calcium-
imaging studies have shown that the somata of sensory neurons
also show sensitization to mechanical and cold stimuli.106,107 These
data indicate that in the murine model of SCD, multiple types
of sensory afferent neurons exhibit spontaneous activity, which is
a correlate of spontaneous pain behavior that is also reported by
patients with SCD.
Electrophysiological recordings indicate action: potential firing
in sensory neurons. Patch-clamp studies measure ion channel
function in sensory neurons. Calcium-imaging studies indirectly
show activation of the sensory neurons via increased free intracellular
calcium levels. Electrophysiological recordings of C fibers have been
performed in humans via microneurography170 in complex regional
pain syndrome,171 erythromelalgia-like symptoms,172,173 and other
neuropathies. Microneurography has been suggested for potential
use as a biomarker for pain, and these recordings could be
performed in patients with SCD.
Molecules that may drive activation and/or sensitization of
peripheral or central neurons within the pain pathway in
SCD. Other potential mechanisms that may drive or contribute to
acute or chronic pain in SCD have been demonstrated in murine
sickle models but remain to be validated in SCD patients. These
include neurogenic inflammatory mediators including: CGRP,
tachykinin receptor 1, endothelin 1, endothelin type A receptor,
and Nav1.8 channels174; chemo chemokine receptor-5 and m
opioid receptors175; ion channels including transient receptor
potential vanilloid 1106; and chemokine ligand 2 receptors,176
Ca/calmodulin-dependent protein kinase II,177 protein kinase
Cd,178 and cannabinoid receptors.179 None have yet been validated
in human studies.
Skin biopsies. Skin biopsy has provided information on the
activation of vascular, inflammatory, and neural systems in BERK
sickle mice.156 Skin biopsies could be performed in patients
with SCD to examine potential pain markers and mechanisms
such as elevation of neurogenic markers (eg, CGRP and SP),
and elevation of receptors for endothelin 1, chemo chemokine
receptor-2, and transient receptor potential vanilloid 1, and
signaling molecules Ca/calmodulin-dependent protein kinase II
a and protein kinase Cd. A limitation of this approach is the risk
of impaired skin healing in patients with SCD.
Grip force strength. Grip force strength can be measured as
a nonevoked quantitative measure and has been used to assess
sustained muscle pain in experimental muscle hyperalgesia in
healthy subjects induced by nerve growth factor180; however,
weak muscle performance, myalgia, and motivation of the patient
may influence outcomes.
Summary of pain recommendations
Table 2 presents the pain panel’s recommendations for prioritization,
recognizing that the gold standard for pain assessment is patient
report. End points proposed here must be used in conjunction with
PROs of pain severity and interference as composite end points.
End points for assessing brain outcomes
in SCD
The brain is very vulnerable to injury in SCD. Prior to the Stroke
Prevention Trial in Sickle Cell Anemia (STOP) trial, ;10% of
children with SCD experienced an overt stroke.181 Approximately
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40% of teens and 50% of 30-year-old adults with SCD experienced
a silent cerebral infarct (SCI).182,183 STOP was a randomized
trial to evaluate whether chronic transfusion could prevent initial
stroke in children with sickle cell anemia at high risk as
determined by transcranial Doppler (TCD). In addition to stroke,
cognitive deficits are common in SCD patients,183-185 as are
educational challenges.186-189 In considering new therapeutic
options, efforts are critically needed to ameliorate the burden of
SCD on the CNS. The brain panel identified 4 categories of end
points and measures that can be used to assess brain outcomes
in SCD patients: TCD, MRI, cognition, and education attainment.
In addition, the biomarkers panel identified key neurological
biomarkers for consideration.
TCD
TCD is used to assess the middle cerebral artery (MCA) and
internal carotid artery (ICA) by determining the highest time
averaged mean of the maximum velocity (TAMMV), a measure
used to stratify patients as to stroke risk. Prevention of the first
stroke (primary prevention) was made possible through the demon-
stration in the United States and Europe that high TAMMV found
through TCD predicted stroke in HbSS and HbS/b0 thalassemia and
that chronic transfusion prevented stroke. TCD results were classified
as normal (,170 cm/s), conditional ($170 to ,200 cm/s),
abnormal ($200 cm/s on 2 occasions) or inadequate based on
TAMMV readings in specific arterial segments. Those with abnormal
TCDs received either monthly blood transfusions or no transfusions,
and those randomized to transfusion had a much better outcome in
terms of stroke (1 stroke, vs 10 in the control group) and also fewer
other medical problems while transfused. TCD screening is recom-
mended for children with HbSS and HbS/b0 thalassemia beginning
at 24 months of age and repeated every 12 months through
16 years of age.190
The suggested threshold for treatment should be based on TAMMV
(not peak systolic velocity) and, using nonimaging TCD techniques,
is TAMMV $200 cm/s whereas for imaging the equivalent is time-
averaged mean maximum velocity $185 cm/s. Abnormal TCD is
defined as 2 TCDmeasurements.200 cm/s or a single measure of
.220 cm/s using the nonimaging technique, and 2 .185 cm/sec
or 1 .205 cm/s using the imaging technique.
Measurements should be done at the terminal portions of ICA
and the proximal portion of MCA. The predictive values of the TCD
measurements in the other intracranial arteries has not been rigorously
addressed and should not be used to stratify into high- and low-risk
groups for future strokes. The greatest benefit would be to determine
whether a participant decreased from the abnormal (meeting the
threshold for transfusion) to the normal range. However, in children
receiving therapy, blood transfusion therapy, or observation, the
rate of strokes is too low (,1 event per 100 patient-years190) to
determine whether persistent abnormal TCD velocities or normal
TCD velocities after therapy are associated with higher or lower
incidence rates of strokes, respectively. There are no data to
suggest that simply decreasing the TAMMV from a normal to
slightly lower velocity is an added benefit.
In children receiving regular blood transfusion therapy with
a goal to keep maximum hemoglobin S level ,30% or hydroxyurea
at maximum tolerated dose for abnormal TCD measurements, there
are limited data suggesting that TCD measurements after
starting therapy predict strokes.191 Interpretation of change in
TCD measurements after starting treatment should be done
cautiously because an absence of a decline in TCD measure-
ments after starting therapy does not translate into an absence
of a treatment benefit191 and may be indicative of stenosis of the
interrogated arterial vessel that will not improve with therapy. In
STOP, for all patients who had stroke including those who had
Table 2. Priority end points and measures for pain (non-PRO) in SCD
Tier Prioritization Domains End point/outcome Direct/indirect Pros Cons
I End points currently being
used and recommended by
the panel
Measure of pain control/
function
Heath care utilization: ED/
hospitalization
Indirect Experience with its use in
SCD and other pain
conditions






II End points with experience in




QST Indirect Not an assessment
of pain
Experience with its use in





Functional neuroimaging High potential for being
secondary or correlative
end point













Need validation with clinical
improvement






Grip force Indirect Can be translated to
humans for further
investigation
Needs further validation with
clinical pain
Facial expression analysis Direct
Skin biopsy Indirect/pathological
changes
Circulating biomarkers Indirect/mechanism based
QST, quantitative sensory testing.
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stroke after starting transfusion, the last evaluable TCD was
abnormal in all cases, suggesting that response to transfusion
may be less effective long-term with advanced disease and
persistent abnormal TCD.192
Limitations include ultrasonographer variability, a large coeffi-
cient of variation of TCD measurement in the same child with
HbSS measured only 3 hours apart (7.6% to 12%), and the high
standard deviation of the TCD measurement in children with
HbSS.193,194
MRI of the brain
Given the high prevalence of SCI, at least 35% and 50% in
children and adults with HbSS, and evidence that SCIs are
associated with infarct recurrence, detection of SCI is an
important component of care. MRI of the brain and a neurolog-
ical examination are the only means to detect an SCI. Some
individuals with an SCI may elect not to be treated because of
the relative high number of treatments (13) needed to prevent 1
cerebral infarct recurrence.195 Furthermore, many providers will
not even screen for SCIs because of the high prevalence and
the perception that the benefits of the transfusions do not
outweigh the risks. However, based on the high prevalence, the
association with cognitive morbidity, and the increased risk of
future neurological recurrence, individuals at risk should be
informed of their risk.
Table 3 presents recommended anatomical MRI measures available
now to assess the number of infarcts/lesions. Of note, the definition
of an SCI is based on work by DeBaun and colleagues in the
Silent Infarct Transfusion Trial: an infarct-like lesion was
defined as an MRI signal abnormality that was at least 3 mm
in 1 dimension and that was visible in 2 planes on fluid-
attenuated inversion recovery (FLAIR) T2-weighted images, as
determined by agreement of 2 of the 3 study neuroradiolo-
gists.195 The members of a neurology committee adjudicated
a lesion as an SCI if the study participant had either a normal
neurologic examination or an abnormality on examination that
could not be explained by the location of the brain lesion or
lesions. An enlarged SCI was defined as a previously identified
SCI that increased by at least 3 mm along any linear dimension
in any plane on MRI. In clinical trials, an adjudication process is
needed to objectively confirm neurologic and imaging findings.
As is the standard in all National Institutes of Health stroke
trials, an adjudication committee is needed to objectively confirm
neurologic and CNS-imaging findings. In the Silent Cerebral
Infarct Multi-Center Clinical Trial, ;7% of all children believed
to have SCI actually had strokes when evaluated by a local
pediatric neurologist and later reviewed by a panel of pediatric
neurologists.195
The neuroimaging recommendations represent the technological
evolution in imaging. The recommendation to establish an infarct
as a 3-mm dimension in 2 planes or 3-dimensional (3D) T2w
FLAIR (reconstructed to 3 orthogonal planes) is currently in use
by a neurology-hematology consortium and multiple clinical centers
with expertise in neurological complications of SCD. However, the
3D T2w FLAIR definition has not been validated in a clinical trial
setting. Although there is interest in hemometabolic measures
and diffusion tensor imaging, these measures would benefit
from additional research to validate the specific measures in
order to quantify change.196 Table 4 suggests additional imaging
measures requiring additional research.
Cognition
The cerebral infarcts associated with SCD most commonly occur in
the frontal, temporal, and parietal lobes. Lesions in these areas are
associated with cognitive deficits in executive function, processing
speed, working memory, and attention. These are all measures of
fluid cognition and are associated with abilities to organize one’s
health care, succeed in school, and maintain a job. These cognitive
deficits exist with or without a history of cerebral infarcts.
Table 5 presents recommended global and domain-specific
measures of cognition based on the age of the person being
assessed. These measures were based on those recommended
by the PhenX panel197 and previous SCD clinical trials.
Based on previous studies, the brain panel also recommends
that the following 3 types of measures be completed to interpret
cognition:
1. A measure of the home or social environment,198 such as the
Home Observation for Measurement of the Environment
(HOME), a semistructured interview and observation tool for
assessing parent-child interaction as well as the quantity
and quality of stimuli present in the home environment. The
HOME has been shown to be a reliable tool that can screen
for developmental delay and is predictive of later academic
achievement.
2. The head of household’s level of educational attainment, which
is also significantly related to a child’s cognition.
Table 3. Recommended anatomic measures for MRI of brain in SCD
3 Tesla MRI method: anatomical (basic) Outcome measure Rationale Duration, min
2D T2w FLAIR (2 planes: axial and coronal) or 3D T2w FLAIR
(reconstructed to 3 orthogonal planes)
1. Infarct (count) Evaluate presence of prior and new overt strokes or silent cerebral
and cerebellar infarcts (SCIs); prior SCI is a risk factor for future
SCI
5-7 (cumulative)
2. White matter lesion (count)
3. Alternative pathology (Dx)
3D T1w MPRAGE 1. Infarct (count) Required with FLAIR to characterize infarct (FLAIR hyperintense,
T1 hypointense); progressive tissue atrophy may be associated
with cognitive decline
5
2. Tissue volume (volume; mm3)
2D T2w 1. Infarct (count) Adds clarity for temporal lobe lesion identification 3
2. Lesion (count)
An adjudication committee is strongly recommended for imaging outcomes.
2D, 2-dimensional; Dx, diagnosis; MPRAGE, Magnetization Prepared–RApid Gradient Echo.
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3. Recording of average daily morphine equivalent dose, based
on a meta-analysis that found association of deficits with chronic
opioid use,199 to include verbal working memory, cogni-
tive impulsivity (risk-taking), and cognitive flexibility (verbal
fluency).
Educational attainment
A child’s primary occupation is to attend school. Complications
from SCD result in children missing, on average, 15 to 22 days of
school per year.187 New therapies could be considered successful
if children were able to attend more school days. For adults, the
process of attending more days of work would also be a positive
change. Higher levels of educational attainment are associated with
better health and greater wealth. The brain panel recommends that
the following questions be asked to assess short-term benefit over
the course of 1 school year:
For missed school days, how many were due to (a) scheduled
(medical appointments) and (b) unpredictable hospitalizations?
For a longer-term study, the following example questions have been
used in BABY HUG and the Silent Cerebral Infarct Transfusion
(SIT) trial to assess educational outcomes in the United States:
a. What is your child’s current grade?
b. Has your child ever been held back or repeated a grade?
i. If yes, how many grades? (1, 2, 3, or more)
c. Does your child have any accommodations because of
learning differences?
d. Check all that apply
i. Special Education Services
ii. 504 plan
iii. IEP-individualized education plan




vi. My child does not receive any accommodation for
learning differences
As a measure of educational attainment for adolescents and adults,
questions can be asked about highest-grade level completed,
Table 4. Additional MRI measures of brain in SCD requiring further research as potential end points in clinical trials
3 Tesla MRI method Outcome measure Rationale
Duration,
min
Head time-of-flight magnetic resonance angiography 1. Vasculopathy (percent; categorical) Noninvasive alternative to head CTA/DSA; categorical
grading (use 0-4)205
5
2. Associated pathology (eg, moya-moya)
Neck time-of-flight magnetic resonance angiography 1. Vasculopathy (percent; categorical) Noninvasive alternative to neck CTA; presence of
cervical vasculopathy extent remains debated in SCD
6
Diffusion tensor imaging 1. White matter structural connectivity Fiber tracking and related parameters (anisotropy,
diffusivity) may indicate white matter damage and
describe symptomatology
6
2. Tract-based spatial statistics
3. Fractional anisotropy, mean diffusivity, etc
Susceptibility weighted imaging 1. Microbleeds (count; volume) Characterize microvascular disease and iron deposition 4
2. Quantitative susceptibility (iron)
3. Venous density
Diffusion-weighted imaging if acute CNS event 1. Acute infarct (count) Inform presence of recent infarcts 1
MR venography if acute CNS event Thrombosis, stenosis Unlikely to be abnormal in asymptomatic
Hemometabolic
Arterial spin labeling 1. Regional cerebral blood flow (mL/100g/min) Inform extent of hypo- or hyperperfusion; hypoperfusion
indicative of tissue-level impairment from
vasculopathy; hyperperfusion marker of how well
parenchyma is responding to anemia and reduced
blood delivery; may also provide indicator of arterial-
venous shunting
4
T2-relaxation-under-spin-tagging 1. OEF (ratio of oxygen consumed to oxygen delivered) Inform extent to which total oxygen delivery is meeting
requirements; elevated OEF may be indicator of new
or recurrent infarct; reduced CMRO2 may indicate
suppressed neuronal activity and new lesion risk
2
2. CMRO2; mL O2/100 g/min; requires CBF
measurement
Phase contrast angiography (head and neck) 1. Quantitative velocity assessment of major intracranial
(eg, first segment MCA) and cervical vessels (ICA,
BA) (mm/s)
Allows for whole-brain CBF assessment (with tissue
volume information), which is not possible with arterial
spin labeling; evaluate elevated flow velocity (provide
comparison for TCD)
Blood oxygenation level-dependent or arterial spin
labeling cerebrovascular reactivity (requires
respiratory stimulus such as hypercapnic or IV/oral
vasodilatory stimulus such as acetazolamide)
1. Cerebrovascular reactivity, an indicator of
microvascular reserve capacity (signal change)
Cerebrovascular reserve will be exhausted when CBF
can no longer increase to compensate for anemia
and/or vasculopathy
8
An adjudication committee is strongly recommended for imaging outcomes. Vasculopathy is a surrogate marker and difficult to measure as an outcome.
BA, basilar artery; CBF, cerebral blood flow; CMRO2, cerebral metabolic rate of O2 consumption; CTA, computed tomographic angiography; DSA, digital subtraction angiography; MR,
magnetic resonance; OEF, oxygen extraction fraction.

















L user on 29 D
ecem
ber 2019
graduation status from high school, and dropout from high school.
These measures would be used to assess changes over at least
1 year to balance the variation in seasons of weather and longer-
term benefit. With global studies, regional differences in
educational systems will necessitate different measures of educa-
tional attainment.
Neurological biomarkers
Biomarkers for neurological disorders are potentially valuable for
early identification of children at increased risk of life-changing
complication and to allow aggressive disease-modifying treat-
ments as appropriate. Additionally, some neurological bio-
markers are likely to be valuable as surrogate end points for
therapeutic trials.
As with many complications in SCD, the genotype underlying SCD
is particularly important in determining the risk of cerebrovascular
disease, with overt cerebral infarction, SCI, and vasculopathy all
significantly more common in HbSS than HbSC disease, and
probably the many different types of HbS/thalassemia.181 Nearly all
biomarker studies have been undertaken on patients with HbSS,
with relatively little known about HbSC disease. Similarly, nearly all
studies have been undertaken in Europe and the United States, with
little known about predicting severity in Africa where the disease is
most common.
Biomarkers for overt infarctive stroke. As described in
"TCD," the measurement of TCD velocities in children with SCD
(HbSS and HbSb0 thalassemia) between the ages of 2 and
16 years is 1 of the most established biomarkers in SCD in general.
TCD velocities have also been used as end points in clinical trials,
most notably in a comparison of blood transfusion and hydroxy-
urea.200 Other established biomarkers of overt stroke include low
hemoglobin, high systolic blood pressure, and low overnight
oxygen saturation. Numerous studies have tried to identify genetic
biomarkers associated with increased risk of overt stroke, including
genome-wide association studies, although no consistent, vali-
dated markers emerge other than the absence of thalassemia. Two
genetic markers in tumor necrosis factor and ENPP1 genes have
been confirmed in .1 study, although the effect of each of these
markers appears to be small and they have not yet been clinically
useful.201 Other future biomarkers for stroke in a pediatric SCD
population include circulating plasma levels of soluble receptor for
advanced glycation end products202 and CD341 hematopoietic
stem cell counts (sensitivity, 53%; specificity, 84% for a threshold of
8675 cells per milliliter).203
Biomarkers for SCI. As referenced previously, SCIs are
identified by brain MRI, which is difficult and expensive to perform,
particularly in young children who require general anesthesia for
the procedure. Reliable biomarkers would therefore be particularly
useful, although none are well established either in clinical trials or
practice. Low hemoglobin, particularly in young children, is associated
with increased risk of SCI, and 1 study suggested that regular
transfusion reduces the risk of further SCIs developing.195 Other
identified biomarkers include increased systolic blood pressure,
male sex, and extracranial stenosis of the internal carotid artery.
Future biomarkers for SCI in children with SCD have also been
reported in circulating plasma via a proteomic analysis, identifying
proteins involved in hypercoagulability (a2-antiplasmin, fibrinogen-g
chain, thrombospondin-4), inflammation (a2-macroglobulin, com-
plement C1s and C3), and atherosclerosis (apolipoprotein B-100)
as well as higher levels of gelsolin and retinol-binding protein 4 in
a population with silent infarcts, both of which have been previously
linked to stroke.204
SCD is associated with an increased risk of various other neuro-
logical conditions, including intracranial hemorrhage, seizures,
ognitive impairment (reduced IQ and processing speed), retinop-
athy, deafness and psychiatric disorders although very little information
is available on biomarkers for these complications.
Table 5. Global and domain-specific measures to assess cognitive skills in SCD
Measure Age range Domains Additional considerations
Global measures
Bayley-III 0-3.5 y Cognitive, motor, language, social-emotional,
and adaptive behavior
WPPSI-IV 2 y, 6 mo to 7 y, 7 mo Working memory, processing speed, fluid reasoning,
and visual, spatial, and verbal comprehension
Consider WPPSI cancellation (attention/processing
speed)
WISC-V 6-16 y 11 mo Verbal comprehension, processing speed,
visual spatial, working memory, and fluid reasoning
Consider WPPSI cancellation (attention/processing
speed)
Domain-specific measures
Trails A and B; Trail Making Test, Part A 9 y and older Executive function D-KEFS tower Wisconsin card sorting
Children’s Memory Scale 5-16 y Working memory
The Digit Span Test (Forward and Backward) 16 y and older Working memory Part of the WAIS23
NIH Toolbox DCCS Test 3-85 y Executive function–cognitive flexibility Takes 4 min
NIH Toolbox Flanker Inhibitory Control and
Attention Test
3-85 y Executive function and attention Takes 3 min
NIH Toolbox Pattern Comparison Processing
Speed Test
7-85 y Processing speed Takes 3 min
These tests have not been demonstrated to be superior to several other well-recognized age-specific tests for people with SCD in national and international assessments.
Bayley-III, Bayley Scales of Infant and Toddler Development, Third Edition; DCCS, Dimensional Change Card Sort Test; D-KEFS, Delis-Kaplan Executive Function System; NIH, National
Institutes of Health; WAIS, Wechsler Adult Intelligence Scale; WISC-V, Wechsler Intelligence Scale for Children Fifth Edition; WPPSI-IV, Wechsler Preschool and Primary Scale of
Intelligence Fourth Edition.
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Summary of brain outcome measures
Table 6 provides a summary of the brain panel’s recommended end
points to consider in SCD disease.
Conclusions
Patients with SCD have significant complications due to complex
pathophysiology. Identifying optimal end points for current use and
future development was the goal of the ASH-FDA Sickle Cell
Disease Clinical Endpoints Workshop. This report, along with
the companion report, noted where data exist to support
including clinical trial end points as a direct benefit, surrogate,
or biomarker. In addition, the report identifies where future work
is needed to develop additional end points in SCD. The results
of this work provide an exhaustive list of suggested direct end
points, surrogate end points, and biomarkers, along with future
development recommendations. As with any recommendations,
the exact clinical context must be considered before clinical trial
end point adoption.
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